** Divi's Laboratories DIVI.NS rises ~5% in second session
of gains post Q3 results
** Co's custom synthesis segment grows 45% y/y in Q3
** BOB Capital upgrades to "hold" from "sell", citing co's
effective opportunity utilisation in the fast growing segment
** Jefferies retains "hold" despite custom synthesis
improving product mix and profit
** Says co needs to overcome high rev concentration of key
heart failure drug the patent for which will expire in 2026
** Co working on glucose stabilising hormone GLP-1
manufacturing process to diversify
** Systematix Equities says DIVI seeing interest in GLPs
from several MNCs; has strong position due to backward
integration
** But retains "sell" on rich stock valuation
** DIVI rated "hold" on avg; mean PT of 5,427 rupees is
12.2% downside to current price of 6,185.7 rupees
** Stock up 66% YTD
(Reporting by Ananta Agarwal in Bengaluru)
((Ananta.Agarwal@thomsonreuters.com))